Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LNTH Stock Forecast 2026-2027
$104.52
Current Price
$6.80B
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LNTH Price Targets
+11.9%
To High Target of $117.00
+1.4%
To Median Target of $106.00
-27.3%
To Low Target of $76.00
LNTH Price Momentum
+4.5%
1 Week Change
+11.3%
1 Month Change
+34.3%
1 Year Change
+57.1%
Year-to-Date Change
0.0%
From 52W High of $104.57
+121.2%
From 52W Low of $47.25
📊 TOP ANALYST CALLS
Did LNTH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lantheus is one of their latest high-conviction picks.
Latest LNTH Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LNTH has a bullish consensus with a median price target of $106.00 (ranging from $76.00 to $117.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $104.52, the median forecast implies a 1.4% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LNTH Analyst Ratings
11
Buy
2
Hold
0
Sell
LNTH Price Target Range
Low
$76.00
Average
$106.00
High
$117.00
Current: $104.52
Latest LNTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LNTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2026 | Mizuho | Anthony Petrone | Outperform | Maintains | $115.00 |
| May 11, 2026 | Truist Securities | Buy | Reiterates | $N/A | |
| May 8, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| May 8, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Apr 15, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Apr 13, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 2, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Feb 27, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Feb 27, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Feb 27, 2026 | Jones Trading | Hold | Downgrade | $N/A | |
| Feb 24, 2026 | Citizens | Market Outperform | Maintains | $N/A | |
| Dec 18, 2025 | Truist Securities | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Dec 12, 2025 | Truist Securities | Buy | Upgrade | $N/A | |
| Nov 10, 2025 | Truist Securities | Hold | Reiterates | $N/A | |
| Oct 8, 2025 | Goldman Sachs | Neutral | Downgrade | $N/A | |
| Sep 16, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Sep 15, 2025 | TD Cowen | Buy | Maintains | $N/A | |
| Aug 12, 2025 | Truist Securities | Hold | Downgrade | $N/A | |
| Aug 7, 2025 | JMP Securities | Market Outperform | Maintains | $N/A |
Lantheus Holdings, Inc. (LNTH) Competitors
The following stocks are similar to Lantheus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lantheus Holdings, Inc. (LNTH) Financial Data
Lantheus Holdings, Inc. has a market capitalization of $6.80B with a P/E ratio of 24.9x. The company generates $1.55B in trailing twelve-month revenue with a 18.0% profit margin.
Revenue growth is +1.2% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +23.5%.
Valuation Metrics
Market Cap
$6.80B
Enterprise Value
$6.93B
P/E Ratio
24.9x
PEG Ratio
0.3x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
+1.2%
Gross Margin
+61.2%
Operating Margin
+21.6%
Net Margin
+18.0%
EPS Growth
+62.3%
Financial Health
Cash/Price Ratio
+7.3%
Current Ratio
2.8x
Debt/Equity
51.6x
ROE
+23.5%
ROA
+8.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lantheus Holdings, Inc. (LNTH) Business Model
About Lantheus Holdings, Inc.
What They Do
Develops radiopharmaceutical products for diagnostics and therapy.
Business Model
The company focuses on creating and commercializing diagnostic and therapeutic radiopharmaceuticals, primarily for heart disease and cancer. It generates revenue through the sale of its products, which include agents for imaging and treatment, as well as innovative AI solutions that enhance diagnostic capabilities.
Additional Information
Founded in 1956 and headquartered in Billerica, Massachusetts, the company emphasizes precision medicine and strategic partnerships to advance its offerings. Its diverse portfolio includes products for various medical fields, and it is actively expanding into areas such as Alzheimer's diagnostics.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
808
CEO
Ms. Mary Anne Heino
Country
United States
IPO Year
2015
Website
www.lantheus.comLantheus Holdings, Inc. (LNTH) Latest News & Analysis
Latest News
Quick Summary
Lantheus Holdings (LNTH) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, discussing its business developments and future outlook.
Why It Matters
Lantheus Holdings' presentation at a major healthcare conference may signal strategic plans and potential growth, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Lantheus Holdings (NASDAQ: LNTH) announced that its LNTH-2513 PET/CT imaging received SNMMI's Image of the Year award at the 2026 Annual Meeting, highlighting its efficacy in detecting DVT.
Why It Matters
Lantheus Holdings' recognition at a major industry event highlights its innovative advancements, potentially boosting market confidence and influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lantheus Holdings (NASDAQ: LNTH) announced that VP John Wiggins will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 3, 2026, at 8:40 a.m.
Why It Matters
Lantheus's participation in a major healthcare conference highlights its market presence and potential investor interest, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lantheus Holdings (NASDAQ: LNTH) announced that John Wiggins, VP of External Manufacturing, will speak at the William Blair Growth Stock Conference on June 3 at 12:10 p.m. ET.
Why It Matters
Lantheus's participation in a major conference highlights its strategic focus and potential for growth, signaling to investors the company's commitment to innovation and market engagement.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lantheus Holdings is considering a sale following a takeover offer from Curium Pharma, potentially valuing the company at around $7 billion, according to Bloomberg News.
Why It Matters
Lantheus Holdings' potential sale could significantly impact its stock price, reflecting market interest and influencing investor sentiment in the healthcare sector.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Lantheus Holdings, Inc. (NASDAQ: LNTH) will present new radiodiagnostic data at the SNMMI Annual Meeting from May 30 to June 2, 2026, in Los Angeles, CA.
Why It Matters
New radiodiagnostic data could enhance Lantheus Holdings' market position and attract investor interest, potentially impacting stock performance following the SNMMI Annual Meeting.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LNTH Stock
What is Lantheus Holdings, Inc.'s (LNTH) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Lantheus Holdings, Inc. (LNTH) has a median price target of $106.00. The highest price target is $117.00 and the lowest is $76.00.
Is LNTH stock a good investment in 2026?
According to current analyst ratings, LNTH has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $104.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LNTH stock?
Wall Street analysts predict LNTH stock could reach $106.00 in the next 12 months. This represents a 1.4% increase from the current price of $104.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lantheus Holdings, Inc.'s business model?
The company focuses on creating and commercializing diagnostic and therapeutic radiopharmaceuticals, primarily for heart disease and cancer. It generates revenue through the sale of its products, which include agents for imaging and treatment, as well as innovative AI solutions that enhance diagnostic capabilities.
What is the highest forecasted price for LNTH Lantheus Holdings, Inc.?
The highest price target for LNTH is $117.00 from at , which represents a 11.9% increase from the current price of $104.52.
What is the lowest forecasted price for LNTH Lantheus Holdings, Inc.?
The lowest price target for LNTH is $76.00 from at , which represents a -27.3% decrease from the current price of $104.52.
What is the overall LNTH consensus from analysts for Lantheus Holdings, Inc.?
The overall analyst consensus for LNTH is bullish. Out of 2 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $106.00.
How accurate are LNTH stock price projections?
Stock price projections, including those for Lantheus Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 15, 2026 3:16 AM UTC